VitroScan B.V. is a Dutch biotech start-up company focusing on the development of diagnostic tests to improve selection of drug treatment for cancer patients.
Functional testing: Ex vivo testing of tumor tissue (avatar mice, patients samples, 2D cultures, organoids) is acquiring an important position to boost Personalized Medicine for cancer patients.
VitroScans’ best-in-class technology is based on testing drug sensitivity on 3D tumor cultures from patients. The Drug Response Platform combines extensive expertise in 3D tissue culture, advanced imaging, and high throughput drug response analysis.
Drug Response Database
VitroScan applies a systematic approach to test drugs targeting the relevant cancer pathways. Data acquired in trials for multiple solid tumors from patients are the basis to correlate drug sensitivity, and genetic analysis with clinical outcome.
The Drug Response Database offers opportunities to benchmark drug responses for novel drugs against standard of care treatment, correlate drug response between multiple tumor types, and identify predictive biomarkers.